Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180608 | 0.84 | HSD11B1 (0.49) | MEN1KMT2AHSD11B1SLC22A12CA2 | |
| SCHEMBL6929900 | 0.79 | CA2 (0.44) | MEN1KMT2AHSD11B1SLC22A12CA2 | |
| SCHEMBL10179703 | 0.78 | MEN1 (0.38) | MEN1KMT2AHSD11B1SLC22A12CA2 | |
| SCHEMBL14349353 | 0.78 | BCAT2 (0.37) | MEN1KMT2AHSD11B1ALDH1A1TSHR | |
| SCHEMBL16019344 | 0.74 | PSIP1 (0.43) | MEN1KMT2AHSD11B1ALDH1A1TDP1 | |
| SCHEMBL9965492 | 0.74 | HSD11B1 (0.47) | MEN1KMT2AHSD11B1CA2ALDH1A1 | |
| SCHEMBL16019345 | 0.73 | ADRA2A (0.35) | MEN1KMT2AHSD11B1SLC22A12 | |
| SCHEMBL856017 | 0.72 | KMT2A (0.55) | MEN1KMT2AHSD11B1SLC22A12ALDH1A1 | |
| SCHEMBL945367 | 0.71 | MEN1 (0.40) | MEN1KMT2AHSD11B1SLC22A12CA2 | |
| SCHEMBL6264610 | 0.71 | CA2 (0.43) | MEN1KMT2ACA2CA1CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | PRDX6, PRDX1, CBR3 | MEN1 4302/4885KMT2A 1922/4885HSD11B1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.